Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Intellia Therapeutics reported additional positive Phase 3 data for its CRISPR-based therapy lonvo-z in hereditary angioedema, presented at the EAACI Congress and published in the New England Journal of Medicine. The trial met its primary endpoint with an 87% reduction in monthly attacks versus placebo, and 62% of patients were entirely attack-free during the six-month evaluation period. With a BLA already submitted to the FDA in April, these results support the company’s expectation of regulatory approval and a U.S.
Key figures
- Drug Name
- lonvoguran ziclumeran (lonvo-z)
- Phase Of Trial
- Phase 3
- Ae qol improvement
- -17.04
- Attack free patients
- 62%
- Primary endpoint reduction
- 87%
- On demand treatment reduction
- 89%
- Moderate severe attack reduction
- 91%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.